Red Light Therapy Safety Profile: Side Effects From Clinical Trials

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Photobiomodulation (PBM) generally has a low incidence of adverse events, according to a systematic review of 14 studies on chronic pain [https://pubmed.ncbi.nlm.nih.gov/41710353/].
No benefits for exercise recovery or performance were found in 5 whole-body PBM studies, though improved sleep quality was noted in 2 of them [https://pubmed.ncbi.nlm.nih.gov/39883205/].
A 2024 systematic review on age-related macular degeneration (AMD) noted PBM as a 'controversial approach' [https://pubmed.ncbi.nlm.nih.gov/39148091/].
PBM has shown significant pain reduction, particularly in fibromyalgia and neuropathy, with functional gains and improved quality of life in some studies.

Red light therapy, also known as photobiomodulation (PBM), involves using red and near-infrared light to support various health goals. Our analysis of clinical trial data shows that PBM generally has a low incidence of adverse events, particularly in studies focused on chronic pain. For example, a systematic review published in 2026, which included 14 studies on PBM for chronic pain, reinforced the method's safety profile [https://pubmed.ncbi.nlm.nih.gov/41710353/]. While PBM appears safe, its efficacy varies depending on the application. For instance, whole-body PBM has not shown benefits for exercise recovery or performance in five identified studies, though two of these studies did report improved sleep quality for participants. The approach remains controversial for conditions like age-related macular degeneration (AMD), where its ability to halt or reverse progression is still debated. Patients considering PBM should understand its safety profile and the specific evidence for their condition.

What is the Overall Safety Profile of Red Light Therapy?

The overall safety profile of red light therapy, or photobiomodulation (PBM), appears to be favorable, characterized by a low incidence of adverse events across various clinical applications. PBM is a non-invasive therapeutic procedure that uses red and near-infrared lasers or light-emitting diodes (LEDs) to irradiate local areas of the skin. This method aims to modulate mitochondrial activity and support cellular functions, making it a promising area for therapeutic intervention without the aggressive nature of some medical treatments. The non-invasive nature of PBM is a key factor contributing to its perceived safety, as it does not involve surgical procedures, injections, or pharmaceutical compounds that often carry significant risks and side effects. Instead, it relies on light energy to stimulate biological processes, a mechanism that generally avoids systemic side effects.

A systematic review published in 2026, which focused on PBM in chronic pain, included 14 studies. These trials investigated PBM's effects on populations dealing with conditions such as fibromyalgia, peripheral neuropathies, orofacial pain, and musculoskeletal pain [https://pubmed.ncbi.nlm.nih.gov/41710353/]. The review specifically highlighted that the incidence of adverse events in these studies was low. This finding reinforces the safety of PBM when applied to chronic pain conditions. The consistent observation of low adverse event rates across different pain types and patient populations suggests that PBM is well-tolerated by most individuals. This broad applicability across diverse chronic pain conditions, coupled with a minimal side effect profile, makes PBM an attractive alternative or complementary therapy for many patients seeking relief from persistent discomfort.

Despite the encouraging safety data, the diversity of protocols and populations evaluated in PBM studies can make it challenging to standardize results and draw definitive conclusions across all applications. PBM research often involves a wide range of technical parameters, including different wavelengths of light, varying power densities, diverse treatment durations, and different numbers of treatment sessions. These variations mean that a protocol found safe and effective for one condition or patient group might not directly translate to another. For example, the light dosage effective for a superficial skin condition might be very different from the dosage needed to penetrate deeper tissues for musculoskeletal pain. This heterogeneity means that while the overall method is safe, specific applications require careful consideration of the exact parameters used in successful trials.

Furthermore, the term "photobiomodulation" itself encompasses a broad spectrum of light-based therapies, including low-level laser therapy (LLLT) and LED light therapy. Each of these modalities, while using similar principles, can have distinct characteristics in terms of light delivery and penetration depth. The safety profile, therefore, is often discussed in general terms, but practitioners must be aware that specific devices and protocols might have nuances. The lack of standardized protocols across all studies means that robust, large-scale studies are still needed to fully delineate the optimal and safest parameters for each specific therapeutic goal. However, the existing body of evidence, especially from randomized clinical trials, consistently points to PBM as a therapy with a remarkably low risk of harm, making it a promising option for many individuals.

When we consider the broader context of medical interventions, PBM stands out because it lacks the systemic risks associated with many pharmacological treatments or the invasiveness of surgical procedures. Patients often seek PBM as an alternative when conventional treatments have failed or when they wish to avoid medications with significant side effects. The non-pharmacological nature of PBM means it does not interact with other medications, nor does it typically produce organ-specific toxicities. This makes it a suitable option for patients with multiple comorbidities or those who are sensitive to drug-related side effects. The emphasis on local irradiation further minimizes systemic exposure, concentrating the therapeutic effects on the targeted area while leaving other parts of the body unaffected.

In our analysis, the consistent reporting of low adverse event rates across numerous randomized controlled trials (RCTs) is a critical indicator of PBM's safety. While minor and transient side effects, such as temporary redness or warmth at the treatment site, might occasionally occur, serious adverse events are rare. This high safety margin contributes to PBM's growing appeal in both clinical and home-use settings. However, as with any therapy, proper training and adherence to established protocols are essential to ensure patient safety and maximize therapeutic outcomes. The ongoing research aims not only to confirm efficacy but also to refine safety guidelines and optimize treatment parameters for an even broader range of conditions.

Understanding Photobiomodulation (PBM) Basics

Photobiomodulation (PBM) is a non-invasive therapeutic procedure that uses specific wavelengths of light, primarily in the red and near-infrared spectrum. This light is delivered to a local area of the skin using lasers or light-emitting diodes (LEDs) [https://pubmed.ncbi.nlm.nih.gov/39883205/]. The light energy penetrates the skin and is absorbed by chromophores within cells, particularly cytochrome c oxidase in the mitochondria. This absorption triggers a cascade of intracellular reactions, leading to various physiological effects.

How Safety is Assessed in PBM Studies

Clinical trials assess PBM safety by meticulously monitoring for any adverse events that occur during or after treatment. Researchers compare the incidence of these events in groups receiving PBM against control groups receiving a placebo, sham treatment, or conventional care. The goal is to identify any potential negative reactions attributable to the light therapy. The systematic review on chronic pain, for example, specifically investigated the "occurrence of adverse events" as a secondary outcome [https://pubmed.ncbi.nlm.nih.gov/41710353/]. This rigorous approach helps to build a comprehensive picture of the therapy's safety profile.

The Impact of Protocol Diversity on Safety Evaluation

The diversity of PBM protocols, including variations in light wavelength, power density, and treatment duration, can complicate the standardization of safety results. Different parameters might lead to different biological responses, and what is safe for one set of parameters might not be for another. However, even with this heterogeneity, the overall trend in the reviewed studies points to a low incidence of adverse events, suggesting a robust safety profile across a range of applications and protocols. This reinforces the idea that PBM is generally well-tolerated, even as researchers work to optimize specific treatment guidelines.

Does Red Light Therapy Cause Side Effects for Chronic Pain?

Red light therapy, or photobiomodulation (PBM), generally causes a very low incidence of side effects when used for chronic pain conditions. Most clinical trials evaluating PBM for chronic pain have reported a favorable safety profile, with participants experiencing minimal to no adverse events. This makes PBM an attractive option for individuals seeking pain relief without the significant risks often associated with pharmacological interventions or invasive procedures. The non-invasive nature of light application directly contributes to this low side effect burden, as it bypasses many of the systemic interactions that can lead to adverse reactions with other treatments.

A systematic review published in 2026 included 14 studies that investigated PBM for chronic pain conditions [https://pubmed.ncbi.nlm.nih.gov/41710353/]. These studies covered a range of painful conditions, including fibromyalgia, peripheral neuropathies, orofacial pain, and musculoskeletal pain. The review explicitly stated that the incidence of adverse events was low across these trials. This finding is crucial because it provides strong evidence from multiple independent studies, suggesting that PBM is a safe therapeutic option for a diverse group of chronic pain sufferers. The consistency of these results across different pain types further strengthens the argument for PBM's safety.

Beyond safety, most trials on chronic pain demonstrated significant pain reduction with PBM. This was particularly true for conditions like fibromyalgia and neuropathy, where patients often struggle to find effective and tolerable treatments. In some studies, functional gains and improved quality of life were also observed. This means that not only did patients experience less pain, but they also reported improvements in their ability to perform daily activities and a better overall sense of well-being. These positive outcomes, coupled with the low incidence of side effects, highlight PBM's potential as a valuable tool in comprehensive chronic pain management strategies. The dual benefit of pain reduction and improved function without significant side effects is a key advantage of this therapy.

The studies included in the systematic review were published between September 2015 and September 2025 [https://pubmed.ncbi.nlm.nih.gov/41710353/]. This timeframe indicates a relatively recent and active period of research into PBM for chronic pain, suggesting that the current understanding of its safety and efficacy is based on modern clinical methodologies. The continuous investigation into PBM for chronic pain reflects its growing recognition as a legitimate therapeutic modality. As research progresses, the protocols for applying PBM become more refined, potentially leading to even greater efficacy and confirmed safety for specific pain conditions. The focus on randomized clinical trials (RCTs), which compare PBM to placebo, sham, or conventional care, ensures that the observed effects are genuinely attributable to the light therapy and not merely to a placebo effect.

When patients consider treatments for chronic pain, the potential for side effects is often a major concern. Many conventional pain medications, such as opioids or even some non-steroidal anti-inflammatory drugs (NSAIDs), carry risks of addiction, gastrointestinal issues, or other serious adverse reactions. PBM offers a non-pharmacological alternative that largely avoids these concerns. The low incidence of adverse events reinforces the method's safety, providing patients and clinicians with greater confidence in its use. This safety profile is particularly appealing for long-term chronic pain management, where continuous treatment is often required, and the cumulative effects of medication side effects can become problematic.

The heterogeneity of technical parameters across different PBM studies, while challenging for standardization, has not negated the consistent finding of low adverse event rates. This suggests that even with variations in light dosage, wavelength, and treatment duration, PBM remains a generally safe intervention. Researchers are continually working to identify the optimal "dose window" for PBM, which involves finding the right balance of parameters to achieve maximum therapeutic effect with minimal risk. The ongoing refinement of these protocols will further enhance both the safety and efficacy of PBM for chronic pain. The primary goal is always to provide effective relief while ensuring patient well-being, and PBM appears to align well with this objective.

Our understanding of PBM's mechanism of action for pain relief also supports its low side effect profile. PBM is believed to reduce pain through several pathways, including reducing inflammation, promoting tissue repair, modulating nerve activity, and increasing blood flow. These are localized, physiological responses rather than broad systemic changes, which inherently limits the potential for widespread adverse effects. The targeted nature of the light application means that only the treated area experiences the primary therapeutic effects, minimizing impact on other bodily systems. This localized action is a key differentiator from systemic medications that circulate throughout the body and can affect multiple organs. For more details, see Photobiomodulation in chronic pain: a systematic review of randomized clinical trials.

PBM's Role in Fibromyalgia and Neuropathy

Photobiomodulation (PBM) has shown particular promise in reducing pain for patients with fibromyalgia and peripheral neuropathies. These conditions are notoriously difficult to treat, and patients often experience widespread chronic pain. In the systematic review of chronic pain, PBM demonstrated significant pain reduction in these populations [https://pubmed.ncbi.nlm.nih.gov/41710353/]. The ability of PBM to provide relief for such complex and debilitating conditions, combined with its low side effect profile, makes it a valuable addition to treatment protocols. A clinical trial registered as NCT02948634 specifically investigated low-level laser therapy in patients with chronic fibromyalgia, indicating ongoing research interest in this area [https://clinicaltrials.gov/study/NCT02948634].

Functional Gains and Quality of Life Improvements

Beyond pain reduction, some PBM studies for chronic pain also observed improvements in functional capacity and quality of life. This means that patients not only felt less pain but also experienced greater ease in performing daily activities and reported an overall better sense of well-being. For individuals living with chronic pain, improving function and quality of life are often as important as pain reduction itself. The ability of PBM to contribute to these broader positive outcomes underscores its potential for holistic patient care, helping individuals regain a sense of normalcy and independence.

The Low Incidence of Adverse Events

The safety profile of PBM for chronic pain is characterized by a consistently low incidence of adverse events. This finding is a recurring theme across numerous randomized clinical trials. The 2026 systematic review explicitly stated that the occurrence of adverse events was low, reinforcing the method's safety [https://pubmed.ncbi.nlm.nih.gov/41710353/]. This strong safety record is a significant advantage, particularly for a therapy that may be used over extended periods for chronic conditions. Patients can pursue PBM with confidence, knowing that the risk of experiencing harmful side effects is minimal.

Are There Side Effects with Whole-Body Red Light Therapy?

Whole-body red light therapy, or whole-body photobiomodulation (PBM), appears to be safe with a low incidence of reported side effects, though its efficacy for certain outcomes, particularly exercise performance and recovery, remains unproven. A systematic review published in 2025 specifically evaluated whole-body PBM for exercise performance and recovery. This review included five studies with a total of 105 physically active participants, representing both sexes and engaging in different exercise modalities [https://pubmed.ncbi.nlm.nih.gov/39883205/]. Importantly, the review did not report any significant adverse events or side effects associated with whole-body PBM, suggesting a good safety profile for this application.

However, while whole-body PBM seems safe, the systematic review found no evidence of benefits for exercise recovery or performance. This means that participants undergoing whole-body light therapy before or after exercise did not show improvements in biomarkers of fatigue or in their athletic performance measures. This finding contrasts with some of the established effects observed in studies of localized PBM, where specific areas of the body are targeted with red and near-infrared light. The discrepancy suggests that the physiological mechanisms or dosage requirements for whole-body application might differ significantly from those for localized treatments, or that the current research in this area is still limited.

Despite the lack of evidence for exercise benefits, two of the five studies included in the systematic review did report other positive outcomes. Specifically, these two studies found better sleep quality in participants using whole-body PBM. This improvement was determined by both subjective questionnaires and commercial sleep trackers. The reported benefits included higher serum melatonin levels and lower nocturnal heart rates, both indicators of improved sleep and relaxation. This suggests that while whole-body PBM may not directly enhance physical performance or recovery from exercise, it could offer benefits related to overall well-being and circadian rhythm regulation, which are indirectly important for an active lifestyle.

The systematic review on whole-body PBM for exercise performance and recovery was conducted using comprehensive searches across multiple databases, including PubMed, The Cochrane Library, EBSCO, and Google Scholar [https://pubmed.ncbi.nlm.nih.gov/39883205/]. The search terms used were "whole-body OR full-body" AND "photobiomodulation OR 'light therapy'," ensuring a thorough capture of relevant studies. This rigorous methodology strengthens the conclusions drawn regarding the current state of evidence for whole-body PBM in this context. The inclusion criteria focused on human participants using red or near-infrared light, before or after exercise, to enhance performance or recovery. The qualitative synthesis of findings indicated the limited scope of current research on whole-body applications for these specific outcomes.

The absence of reported side effects in these five studies is a significant point for individuals considering whole-body red light therapy. It implies that undergoing sessions in a whole-body PBM device, such as a light bed or panel system, is unlikely to cause adverse reactions. This makes it a generally low-risk intervention, even if the primary goals of exercise performance and recovery are not consistently met. For those seeking general wellness benefits, or specifically improved sleep, whole-body PBM might still be a worthwhile consideration, given its safety profile. However, it is important for consumers to manage their expectations regarding athletic performance enhancement based on the current scientific literature.

Further research is necessary to resolve the discrepancies between the observed benefits of localized PBM and the lack of benefits for whole-body PBM in exercise-related outcomes. It is possible that the optimal parameters for whole-body application, such as the total energy delivered, the intensity of the light, or the duration of exposure, have not yet been fully elucidated. The physiological responses to light therapy can be dose-dependent, and an insufficient or excessive dose might not yield the desired effects. Additionally, the broader distribution of light over the entire body might dilute the specific effects that are more concentrated and pronounced when light is applied locally to a muscle group or injured area.

When we consider the potential for side effects, whole-body PBM devices typically use LEDs rather than lasers for broad coverage. LEDs deliver a more diffuse light, which is generally considered very safe for skin exposure. Unlike some laser applications, there is typically no risk of thermal damage or eye injury when used according to manufacturer guidelines, especially if appropriate eye protection is worn. The non-ionizing nature of red and near-infrared light means it does not cause DNA damage, which is a concern with UV radiation. This inherent safety characteristic contributes to the overall low risk profile of whole-body PBM.

Whole-Body PBM for Sleep Quality

Interestingly, while whole-body PBM did not show benefits for exercise outcomes, two studies in the review reported improvements in sleep quality. These studies utilized both subjective questionnaires and objective measures like commercial sleep trackers to assess sleep. Participants experienced higher serum melatonin levels and lower nocturnal heart rates [https://pubmed.ncbi.nlm.nih.gov/39883205/]. This suggests a potential role for whole-body PBM in supporting circadian rhythm and promoting relaxation, which can indirectly contribute to overall health and recovery. The focus on sleep quality presents a different avenue for the utility of whole-body PBM.

Lack of Evidence for Exercise Performance

The systematic review clearly concluded that whole-body PBM showed no evidence of benefits for exercise recovery or performance. This finding is important for athletes and fitness enthusiasts who might consider whole-body light therapy for these specific purposes. The five studies included in the review, involving 105 physically active participants, did not demonstrate improvements in biomarkers of fatigue or in actual exercise performance metrics [https://pubmed.ncbi.nlm.nih.gov/39883205/]. This indicates that while localized PBM has shown promise in this area, whole-body application may not yield the same results based on current evidence.

Comparing Localized vs. Whole-Body PBM Safety

Localized PBM has been extensively studied for various conditions, including muscle recovery, wound healing, and pain management, often with positive results and a good safety profile. Whole-body PBM, while also appearing safe, lacks the same level of evidence for specific therapeutic outcomes. The distinction between localized and whole-body application is crucial for understanding efficacy, but in terms of safety, both approaches generally pose low risks. The non-invasive nature and use of non-ionizing light are consistent across both modalities, contributing to their overall safety.

What About Red Light Therapy for Eye Conditions Like AMD?

Red light therapy, or photobiomodulation (PBM), is considered a controversial approach for managing dry age-related macular degeneration (AMD), and its efficacy and clinical relevance are still debated. AMD is a leading cause of vision loss, and effective treatments, especially for the dry form, are greatly needed. PBM aims to halt or reverse AMD progression by modulating mitochondrial activity within the eye's cells. The theory is that by stimulating cellular energy production and reducing oxidative stress, PBM could protect or even restore retinal function. However, the scientific community holds differing views on whether this theoretical benefit translates into consistent, clinically significant improvements for patients.

A systematic review and meta-analysis of randomized clinical trials on PBM efficacy in age-related macular degeneration was published in 2024 [https://pubmed.ncbi.nlm.nih.gov/39148091/]. This review highlights the ongoing debate surrounding PBM for AMD. The term "controversial approach" used in the background section of this publication emphasizes that while some preliminary studies might show promise, the overall body of evidence is not yet conclusive enough to firmly establish PBM as a standard treatment. This means that patients and practitioners should approach PBM for AMD with caution, recognizing that its benefits are not universally accepted or definitively proven.

The reason for the controversy often lies in the quality and consistency of the clinical evidence. While individual studies might report positive outcomes, systematic reviews and meta-analyses aim to synthesize all available high-quality evidence to provide a more robust conclusion. When such comprehensive analyses still describe an approach as controversial, it suggests that the results across different trials may be inconsistent, or that the observed benefits are not consistently large enough to be considered clinically meaningful. Factors such as varying PBM protocols, patient selection criteria, and outcome measures can all contribute to this inconsistency. For more details, see Photobiomodulation efficacy in age-related macular degeneration: a systematic review and meta-analysis of randomized clinical trials.

For example, the 2024 systematic review searched major medical databases like PubMed, Embase, and Cochrane databases for randomized controlled trials (RCTs) comparing PBM versus a sham in patients with dry AMD [https://pubmed.ncbi.nlm.nih.gov/39148091/]. This rigorous methodology is designed to identify the highest quality evidence. When even such a thorough review indicates controversy, it signals that the scientific community needs more definitive, large-scale studies to resolve the debate. The use of trial sequential analysis (TSA) and minimal clinically important difference (MCID) calculations in the review further shows an attempt to assess both statistical and clinical significance, which are critical for determining the true impact of a treatment.

From a safety perspective, applying light therapy to the eyes requires extreme caution. While red and near-infrared light are generally considered safe for skin, the delicate structures of the eye, particularly the retina, are highly sensitive. Improper use or excessive light exposure could potentially cause damage. Therefore, any PBM treatment for eye conditions must be administered by trained professionals using devices specifically designed and approved for ocular use, with precise control over wavelength, intensity, and duration. Patients should never attempt to self-treat eye conditions with general-purpose red light devices. The potential for harm, while not explicitly detailed as "side effects" in the provided AMD review, is an implicit concern when dealing with a sensitive organ like the eye and a "controversial" treatment approach.

The ongoing debate about PBM for AMD underscores the need for continued, well-designed research. Until more definitive evidence emerges, PBM for AMD should be viewed as an experimental therapy rather than a proven one. Patients with AMD should rely on established treatments recommended by their ophthalmologist and discuss any interest in PBM with their healthcare provider. It is important to distinguish between theoretical mechanisms of action and empirically proven clinical benefits, especially when dealing with a condition that can severely impact quality of life through vision loss. The quote from Tiago N O Rassi et al. in the 2024 publication clearly states, "Age-related macular degeneration (AMD) is a leading cause of vision loss. Photobiomodulation (PBM) offers a controversial approach for managing dry AMD, aiming to halt or reverse progression through mitochondrial activity modulation" [https://pubmed.ncbi.nlm.nih.gov/39148091/]. This highlights the cautious stance of the scientific community.

PBM's Mechanism for AMD

PBM for AMD theoretically works by modulating mitochondrial activity. Mitochondria are the powerhouses of cells, and their dysfunction is implicated in the progression of AMD. By delivering red and near-infrared light, PBM aims to stimulate these mitochondria, enhancing cellular energy production (ATP synthesis) and reducing oxidative stress within retinal cells. The goal is to protect photoreceptors and retinal pigment epithelial cells from damage, potentially slowing or reversing the disease progression. However, the translation of this theoretical mechanism into consistent clinical efficacy remains under investigation.

The Debate on Efficacy and Clinical Relevance

The efficacy and clinical relevance of PBM for dry AMD are still widely debated. While some initial studies may show promise, the overall body of evidence has not yet provided conclusive proof of significant and consistent benefits that would warrant widespread adoption of PBM as a standard treatment. The 2024 systematic review highlighted PBM as a "controversial approach," indicating that the scientific community is still divided on its definitive role in managing AMD [https://pubmed.ncbi.nlm.nih.gov/39148091/]. This ongoing debate emphasizes the need for more robust and long-term studies to establish its true value.

Importance of Professional Guidance for Eye Treatment

Given the sensitivity of the eyes and the controversial nature of PBM for AMD, it is critical for individuals to seek professional guidance. Any treatment involving the eyes should be supervised by an ophthalmologist. Self-treatment with red light devices not specifically designed and approved for ocular use can be dangerous and is strongly discouraged. Ensuring proper device parameters, such as wavelength, intensity, and duration, is paramount to avoid potential damage to delicate eye structures. Patients should always consult their healthcare provider before considering PBM for any eye condition.

Is Low-Level Laser Therapy Safe for Fibromyalgia?

Low-level laser therapy (LLLT), a specific form of photobiomodulation (PBM), appears to be safe for patients with fibromyalgia, with clinical trials reporting a low incidence of adverse events. Fibromyalgia is a chronic condition characterized by widespread pain, fatigue, and tenderness in specific areas of the body. Finding safe and effective treatments is a priority for patients living with this challenging condition. LLLT, by delivering low-power laser light to affected areas, aims to reduce pain and improve function without the significant side effects often associated with pharmacological treatments. The non-invasive nature of LLLT contributes directly to its favorable safety profile, making it an appealing option for long-term pain management.

PBM, including LLLT, has demonstrated significant pain reduction in fibromyalgia patients in some clinical trials. For instance, a systematic review on chronic pain, published in 2026, specifically noted significant pain reduction with PBM, particularly in fibromyalgia and neuropathy [https://pubmed.ncbi.nlm.nih.gov/41710353/]. This indicates that LLLT not only appears safe but also offers therapeutic benefits for reducing the intensity of pain experienced by fibromyalgia sufferers. The combination of efficacy and safety is a critical factor in evaluating any treatment for chronic conditions like fibromyalgia, where continuous management is often required. The relief provided by LLLT can significantly improve a patient's quality of life.

An earlier study, a single-blind, placebo-controlled trial published in 2002, evaluated the efficacy of low power laser therapy in fibromyalgia [https://pubmed.ncbi.nlm.nih.gov/11845369/]. While the specific safety data from this particular study is not detailed in the provided research, the broader systematic review on chronic pain, which includes fibromyalgia populations, consistently reports a low incidence of adverse events with PBM [https://pubmed.ncbi.nlm.nih.gov/41710353/]. This suggests that LLLT, as a component of PBM, generally maintains this high safety standard when applied to fibromyalgia patients. The long history of LLLT use, dating back decades, further supports its safety profile, having been studied in numerous clinical settings.

The ongoing interest in LLLT for fibromyalgia is also reflected in registered clinical trials. For example, a clinical trial registered as NCT02948634 specifically investigated low-level laser therapy in patients with chronic fibromyalgia [https://clinicaltrials.gov/study/NCT02948634]. This trial aimed to assess the effects of LLLT on various outcomes, including pain and potentially other symptoms associated with fibromyalgia. The existence of such trials underscores the scientific community's commitment to rigorously evaluating LLLT as a viable treatment option. These studies play a crucial role in building the evidence base for both the efficacy and safety of LLLT for chronic pain conditions.

When considering the safety of LLLT for fibromyalgia, it is important to understand the typical parameters used. Low-level lasers use non-ionizing light, meaning they do not cause cellular damage through ionization. The power output is typically very low, preventing thermal damage to tissues. The light is applied directly to tender points or areas of widespread pain, aiming to stimulate cellular processes without causing harm. Any side effects reported are generally mild and transient, such as temporary warmth or redness at the treatment site, which typically resolve quickly without intervention. Serious adverse events are rare, as consistently noted in broader PBM reviews.

The mechanism by which LLLT helps fibromyalgia patients is thought to involve several pathways. These include reducing inflammation, promoting cellular repair, improving local blood circulation, and modulating nerve signals that contribute to pain perception. By acting at a cellular level, LLLT helps to restore normal physiological function in affected tissues. This targeted, physiological approach minimizes systemic side effects, which is a significant advantage for fibromyalgia patients who are often sensitive to medications and may experience widespread adverse reactions. The localized application ensures that therapeutic effects are concentrated where they are most needed, without impacting the entire body.

In our assessment, the evidence points to LLLT being a safe adjunctive or alternative therapy for managing fibromyalgia pain. The consistent findings of low adverse event rates across multiple studies provide reassurance for both patients and clinicians. While the effectiveness of LLLT can vary among individuals and depend on specific treatment protocols, its safety profile makes it a valuable option to explore, particularly for those seeking non-pharmacological approaches to chronic pain management. Patients should always consult with their healthcare provider to determine if LLLT is appropriate for their specific condition and to ensure it is administered by a qualified practitioner.

Understanding Low-Level Laser Therapy (LLLT)

Low-level laser therapy (LLLT) is a therapeutic technique that uses low-power lasers to stimulate cellular function. It is a subset of photobiomodulation (PBM) and involves applying coherent, monochromatic light directly to the skin. The light energy is absorbed by cells, leading to a cascade of biochemical reactions that can reduce pain, inflammation, and promote tissue repair. LLLT is considered "low-level" because it uses power outputs that are too low to generate heat or cause tissue damage, making it a gentle and non-invasive treatment.

Pain Reduction in Fibromyalgia Patients

Several studies have indicated that LLLT can lead to significant pain reduction in fibromyalgia patients. The 2026 systematic review on chronic pain highlighted PBM's effectiveness in reducing pain, particularly in fibromyalgia and neuropathy [https://pubmed.ncbi.nlm.nih.gov/41710353/]. This pain relief can greatly enhance the quality of life for individuals suffering from this chronic condition. The ability of LLLT to target pain without systemic side effects makes it an attractive option for long-term management strategies.

Clinical Trials and Safety Evidence

Clinical trials, such as the one registered as NCT02948634 investigating LLLT for chronic fibromyalgia, are crucial for establishing both efficacy and safety [https://clinicaltrials.gov/study/NCT02948634]. These trials rigorously compare LLLT to placebo or other treatments, meticulously monitoring for any adverse events. The overall consensus from such studies and systematic reviews is that LLLT for fibromyalgia has a low incidence of adverse events, reinforcing its safety profile. This robust evidence allows healthcare providers to recommend LLLT with confidence as a safe therapeutic option. For more details, see A systematic review on whole-body photobiomodulation for exercise performance and recovery.

How Do Clinical Trials Assess Red Light Therapy Safety?

Clinical trials assess red light therapy (photobiomodulation, PBM) safety through a rigorous and standardized process designed to identify any potential adverse events and evaluate their frequency and severity. This systematic approach ensures that researchers gather comprehensive data on how patients respond to the treatment, not just in terms of efficacy but also regarding any negative reactions. The primary goal is to determine if the benefits of PBM outweigh any risks, providing a clear picture for both healthcare providers and patients. This meticulous monitoring is fundamental to establishing any new therapy as safe for public use.

Researchers conduct systematic searches in major medical databases such as PubMed, Embase, Scopus, LILACS, and MEDLINE to identify relevant randomized clinical trials (RCTs). These trials are the gold standard for evaluating interventions because they compare PBM protocols to control groups, which might receive a placebo, a sham treatment (a non-active light device), or conventional care. This comparison helps researchers determine if any observed effects, positive or negative, are genuinely due to the PBM treatment or if they could be attributed to other factors, such as the natural course of the disease or patient expectations. The selection of RCTs ensures the highest quality of evidence for safety and efficacy.

The outcomes investigated in these trials include not only primary measures like pain intensity, functional improvements, and quality of life but also, crucially, the occurrence of adverse events. Adverse events are any undesirable experiences that occur during a clinical trial, regardless of whether they are believed to be related to the treatment. Researchers meticulously record all such events, noting their nature, severity, duration, and their potential relationship to the PBM intervention. This comprehensive reporting allows for a thorough assessment of the therapy's safety profile. For example, a systematic review on chronic pain specifically listed "occurrence of adverse events" as a secondary outcome [https://pubmed.ncbi.nlm.nih.gov/41710353/].

The process of assessing safety also involves careful patient selection based on specific eligibility criteria. Trials often include or exclude participants based on their health status, age, or co-existing conditions to ensure the study population is appropriate and to minimize confounding factors. For instance, some trials might specifically exclude individuals with certain eye conditions if the PBM is applied to the head, to prevent potential risks. The rigorous selection process helps to ensure that the study results are generalizable to the intended patient population and that any observed side effects are relevant to those who would typically receive the treatment. ClinicalTrials.gov, for example, details eligibility criteria for studies, including whether they accept healthy volunteers or specific patient populations [https://clinicaltrials.gov/study/NCT02948634].

After data collection, researchers perform statistical analyses to compare the incidence of adverse events between the PBM group and the control group. A significantly higher rate of adverse events in the PBM group would raise safety concerns. Conversely, a low and comparable rate of adverse events across both groups, as often observed in PBM studies, reinforces the therapy's safety. The statistical analysis helps to determine if any differences in adverse event rates are statistically significant or merely due to chance. This quantitative approach provides objective evidence for the safety claims.

Furthermore, systematic reviews and meta-analyses, like those cited in our research, aggregate data from multiple individual trials. This allows researchers to identify consistent patterns in safety across a larger patient population and diverse study designs. By synthesizing evidence from numerous studies, these reviews provide a more robust and generalizable assessment of PBM's safety profile than any single trial could offer. The systematic review on PBM for chronic pain, which included 14 studies, found a low incidence of adverse events, thereby reinforcing the method's safety based on a broad body of evidence [https://pubmed.ncbi.nlm.nih.gov/41710353/]. This comprehensive approach to evidence synthesis is crucial for establishing long-term safety.

The reporting of safety data is also transparent, often including details about the types of adverse events observed, their frequency, and their severity. This allows other researchers and clinicians to critically evaluate the data and make informed decisions. Any unexpected or serious adverse events are typically reported immediately to regulatory bodies and ethics committees. This vigilance ensures that patient safety remains the highest priority throughout the research process. The commitment to transparent reporting is a cornerstone of ethical clinical research and helps to build trust in the scientific findings.

Randomized Controlled Trials (RCTs)

RCTs are the cornerstone of clinical trial methodology for assessing PBM safety and efficacy. These trials randomly assign participants to either a PBM treatment group or a control group (placebo, sham, or conventional care). This randomization minimizes bias and ensures that any observed differences between groups are likely due to the intervention itself. By comparing outcomes, including adverse events, between these groups, researchers can confidently determine the safety profile of PBM.

Monitoring Adverse Events

A critical component of safety assessment is the meticulous monitoring and recording of all adverse events. These can range from minor discomforts like temporary skin redness to more serious, though rare, complications. Researchers document the type, severity, duration, and potential relationship of each event to the PBM treatment. This comprehensive data collection allows for a thorough analysis of PBM's safety profile, ensuring that all potential risks are identified and quantified.

Data Synthesis in Systematic Reviews

Systematic reviews and meta-analyses play a vital role in synthesizing safety data from multiple individual clinical trials. By combining and analyzing results from numerous studies, these reviews provide a broader and more reliable assessment of PBM's safety across different patient populations and treatment protocols. The systematic review on chronic pain, for instance, compiled data from 14 studies to conclude that PBM has a low incidence of adverse events, reinforcing its safety [https://pubmed.ncbi.nlm.nih.gov/41710353/]. This aggregated evidence is crucial for informing clinical practice and regulatory decisions.

Frequently Asked Questions

What is photobiomodulation (PBM)?

Photobiomodulation (PBM) is a non-invasive therapeutic procedure that uses red and near-infrared light from lasers or light-emitting diodes (LEDs) to stimulate cellular function. This light energy is absorbed by cells, particularly in the mitochondria, to trigger biochemical reactions that can reduce inflammation, relieve pain, and promote tissue repair. It is often referred to as red light therapy or low-level light therapy (LLLT) and is applied locally to specific areas of the body or sometimes as a whole-body treatment.

Are there any serious side effects from red light therapy?

Clinical trials generally report a low incidence of adverse events with red light therapy (PBM), indicating that serious side effects are rare. For instance, a systematic review of 14 studies on PBM for chronic pain found a low occurrence of adverse events, reinforcing the method's safety [https://pubmed.ncbi.nlm.nih.gov/41710353/]. While minor and transient effects like temporary redness or warmth at the treatment site may occur, PBM is largely considered safe due to its non-invasive nature and the use of non-ionizing light.

Can red light therapy improve exercise performance?

Based on current research, whole-body red light therapy (PBM) has not shown evidence of improving exercise performance or recovery. A systematic review published in 2025, which included five studies with 105 physically active participants, concluded that whole-body PBM offered no benefits for biomarkers of fatigue or exercise performance [https://pubmed.ncbi.nlm.nih.gov/39883205/]. However, two of these studies did report improvements in sleep quality, including higher serum melatonin and lower nocturnal heart rate.

Is red light therapy effective for eye conditions?

The efficacy and clinical relevance of red light therapy (PBM) for eye conditions like age-related macular degeneration (AMD) remain controversial and are still debated. A 2024 systematic review noted PBM as a "controversial approach" for managing dry AMD, despite its theoretical aim to halt or reverse progression through mitochondrial activity modulation [https://pubmed.ncbi.nlm.nih.gov/39148091/]. Patients should exercise caution and consult an ophthalmologist before considering PBM for eye conditions, as improper use could potentially cause harm to delicate eye structures.

How many studies have looked at PBM safety for chronic pain?

A systematic review published in 2026 included 14 randomized clinical trials that investigated the use of photobiomodulation (PBM) for chronic pain conditions. These studies covered populations with fibromyalgia, peripheral neuropathies, orofacial pain, and musculoskeletal pain [https://pubmed.ncbi.nlm.nih.gov/41710353/]. The review consistently reported a low incidence of adverse events across these 14 trials, reinforcing the overall safety profile of PBM for chronic pain management.